These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36866838)

  • 21. Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab.
    Shen F; Shen W
    Technol Cancer Res Treat; 2022; 21():15330338221106563. PubMed ID: 35903924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isatuximab for the treatment of relapsed/refractory multiple myeloma.
    Richardson PG; Beksaç M; Špička I; Mikhael J
    Expert Opin Biol Ther; 2020 Dec; 20(12):1395-1404. PubMed ID: 33111607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.
    Sunami K; Fuchida SI; Suzuki K; Ri M; Matsumoto M; Shimazaki C; Asaoku H; Shibayama H; Ishizawa K; Takamatsu H; Ikeda T; Maruyama D; Imada K; Uchiyama M; Kiguchi T; Iyama S; Murakami H; Onishi R; Tada K; Iida S
    Hematol Oncol; 2023 Aug; 41(3):442-452. PubMed ID: 36433829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.
    Richardson PG; Harrison SJ; Bringhen S; Schjesvold F; Yong K; Campana F; Le-Guennec S; Macé S; Dimopoulos MA
    Future Oncol; 2021 Dec; 17(34):4797-4812. PubMed ID: 34521277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma.
    Richter J; Lin PL; Garcia-Horton V; Guyot P; Singh E; Zhou ZY; Sievert M; Taiji R
    Cancer Med; 2023 Apr; 12(7):8005-8017. PubMed ID: 36726287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma.
    Koiwai K; El-Cheikh R; Thai HT; Brillac C; Fau JB; Veyrat-Follet C; Risse ML; van de Velde H; Semiond D; Nguyen L
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):928-940. PubMed ID: 34185964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.
    Facon T; Moreau P; Martin TG; Spicka I; Oriol A; Koh Y; Lim A; Mikala G; Rosiñol L; Yağci M; Cavo M; Yong K; Risse ML; Asset G; Schwab S; Martinez G
    Hematol Oncol; 2022 Dec; 40(5):1020-1029. PubMed ID: 35653225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma.
    Carlo-Stella C; Zinzani PL; Sureda A; Araújo L; Casasnovas O; Carpio C; Yeh SP; Bouabdallah K; Cartron G; Kim WS; Cordoba R; Koh Y; Re A; Alves D; Chamuleau M; Le Gouill S; López-Guillermo A; Moreira I; van der Poel MWM; Abbadessa G; Meng R; Ji R; Lépine L; Saleem R; Ribrag V
    Hematol Oncol; 2023 Feb; 41(1):108-119. PubMed ID: 36251503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
    Martin T; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Casca F; Macé S; Risse ML; Moreau P
    Blood Cancer J; 2023 May; 13(1):72. PubMed ID: 37156782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan.
    Tagami N; Uchiyama M; Suzuki K; Shirai H; Seto T; Nishina S; Iida S
    Int J Hematol; 2024 Aug; 120(2):217-228. PubMed ID: 38811413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
    Zucali PA; Lin CC; Carthon BC; Bauer TM; Tucci M; Italiano A; Iacovelli R; Su WC; Massard C; Saleh M; Daniele G; Greystoke A; Gutierrez M; Pant S; Shen YC; Perrino M; Meng R; Abbadessa G; Lee H; Dong Y; Chiron M; Wang R; Loumagne L; Lépine L; de Bono J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.
    Spicka I; Moreau P; Martin TG; Facon T; Martinez G; Oriol A; Koh Y; Lim A; Mikala G; Rosiñol L; Yağci M; Cavo M; Risse ML; Asset G; Macé S; van de Velde H; Yong K
    Eur J Haematol; 2022 Nov; 109(5):504-512. PubMed ID: 35871357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Model-based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients.
    Thai HT; Koiwai K; Shitara Y; Kazama H; Fau JB; Semiond D; Veyrat-Follet C
    CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1846-1858. PubMed ID: 37002644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma.
    Mikhael J; Richter J; Vij R; Cole C; Zonder J; Kaufman JL; Bensinger W; Dimopoulos M; Lendvai N; Hari P; Ocio EM; Gasparetto C; Kumar S; Oprea C; Chiron M; Brillac C; Charpentier E; San-Miguel J; Martin T
    Leukemia; 2020 Dec; 34(12):3298-3309. PubMed ID: 32409691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.
    Delgado J; Zienowicz M; van Hennik PB; Moreau A; Gisselbrecht C; Enzmann H; Pignatti F
    Oncologist; 2021 Nov; 26(11):983-987. PubMed ID: 34213061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of isatuximab in combination with steroids for the treatment of relapsed/refractory multiple myeloma patients exhibiting only biochemical progression-A single center retrospective study.
    Regidor BS; Jew S; Goldwater MS; Beatty BM; Bujarski S; ElSayed A; Danis R; Kim S; Swift R; Schwartz G; Berenson JR
    Eur J Haematol; 2023 Oct; 111(4):628-635. PubMed ID: 37485542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.
    Martin T; Mikhael J; Hajek R; Kim K; Suzuki K; Hulin C; Garg M; Quach H; Sia H; George A; Konstantinova T; Risse ML; Asset G; Macé S; van de Velde H; Moreau P
    Blood Adv; 2022 Aug; 6(15):4506-4515. PubMed ID: 35594559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Joint modelling and simulation of M-protein dynamics and progression-free survival for alternative isatuximab dosing with pomalidomide/dexamethasone.
    Thai HT; Gaudel N; Cerou M; Ayral G; Fau JB; Sebastien B; van de Velde H; Semiond D; Veyrat-Follet C
    Br J Clin Pharmacol; 2022 May; 88(5):2052-2064. PubMed ID: 34705283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isatuximab: Nursing Considerations for Use in the Treatment of Multiple Myeloma.
    Wilmoth J; Colson K; Dubin F; Kellam C
    Clin J Oncol Nurs; 2021 Dec; 25(6):706-712. PubMed ID: 34800109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma.
    Quach H; Parmar G; Mateos MV; Ailawadhi S; Leleu X
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):358-363. PubMed ID: 38519329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.